{
    "organizations": [],
    "uuid": "cc8c710f9eaf1f8cfe6df960c4e67343c529d547",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-thrombogenics-reports-initial-data/brief-thrombogenics-reports-initial-data-from-thr-317-clinical-study-idUSFWN1RG0Z4",
    "ord_in_thread": 0,
    "title": "BRIEF-Thrombogenics Reports Initial Data From THR-317 Clinical Study",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 4 (Reuters) - THROMBOGENICS NV:\n* CLINICAL TRIAL IS TARGETED TO BE INITIATED IN Q2 2018 * ‍STUDY ENROLLED A TOTAL OF 49 PATIENTS, INCLUDED ANTI-VEGF NAÏVE PATIENTS AND AS SUB-OPTIMAL ANTI-VEGF RESPONDERS​\n* ‍THR-317 WAS SAFE AND WELL TOLERATED​\n* ‍NO DOSE-LIMITING TOXICITIES OR RELEVANT SAFETY EVENTS WERE REPORTED AT ANY DOSE LEVEL​\n* ‍DATA SUPPORT INITIATION OF A NEXT STUDY EVALUATING THR-317 IN COMBINATION WITH AN ANTI- VEGF​\n* ‍30% ANTI-VEGF TREATMENT NAÏVE 8MG GROUP SUBJECTS SHOWED A > OR EQUAL TO 15 LETTER GAIN FROM BASELINE\n* 5.3% ANTI-VEGF TREATMENT NAÏVE 4MG GROUP SUBJECTS SHOWED A > OR EQUAL TO 15 LETTER GAIN FROM BASELINE Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-04-04T13:36:00.000+03:00",
    "crawled": "2018-04-05T17:18:47.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "thrombogenics",
        "nv",
        "clinical",
        "trial",
        "targeted",
        "initiated",
        "q2",
        "enrolled",
        "total",
        "patient",
        "included",
        "naïve",
        "patient",
        "safe",
        "well",
        "toxicity",
        "relevant",
        "safety",
        "event",
        "reported",
        "dose",
        "support",
        "initiation",
        "next",
        "study",
        "evaluating",
        "combination",
        "treatment",
        "naïve",
        "8mg",
        "group",
        "subject",
        "showed",
        "equal",
        "letter",
        "gain",
        "baseline",
        "treatment",
        "naïve",
        "4mg",
        "group",
        "subject",
        "showed",
        "equal",
        "letter",
        "gain",
        "baseline",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}